NCT02282930View on ClinicalTrials.gov

Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Progressive IgA NephropathyProteinuria
Interventions
DRUG

ACTH (Acthar) Gel

Injected dose of 80 units subcutaneously twice weekly for 6 months.

Trial Locations (4)

10032

Columbia University Medical Center, New York

32224

Mayo Clinic Jacksonville, Jacksonville

55905

Mayo Clinic in Rochester, Rochester

94304

Stanford University, Palo Alto

Sponsors

Lead Sponsor

Mayo Clinic

Collaborators (1)

Mallinckrodt
All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

lead

Mayo Clinic

OTHER

NCT02282930 - Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression | Biotech Hunter | Biotech Hunter